StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LLYBullishEarningsnews
High materiality9/10

Lilly lifts 2026 guidance on strong Mounjaro and Zepbound momentum

Aug 5, 2026, 6:47 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong revenue growth, raised full-year guidance, and multiple regulatory/pipeline catalysts imply near-term upside potential. While IPR&D charges compress GAAP metrics, non-GAAP economics and cash-flow trajectory remain positive, supporting multiple expansion. Historical parallels include post-earnings raises when growth drivers and pipeline progress align with higher guidance, though dilution from acquisitions can temper sentiment in the near term.

AI summary

What happened, with direct paths to the underlying reporting

Lilly posted a robust Q2 2026 with revenue of $22.97B (+48% YoY) and EPS of $7.94 (GAAP) / $8.38 (non-GAAP), aided by $3.03B of acquired IPR&D charges. The company raised 2026 revenue guidance to $85–$87B and non-GAAP EPS to $35.50–$36.50, offset by the IPR&D costs. Regulatory wins and a busy BD pipeline, plus retatrutide obesity data and significant manufacturing expansion in Indiana, support durable growth and potentially higher valuation ahead.

  • Q2 2026 revenue $22,974M, +48% YoY, led by Mounjaro and Zepbound.
  • GAAP EPS $7.94; non-GAAP EPS $8.38; includes $3.03 acquired IPR&D charges.
  • Raised 2026 revenue guidance to $85–$87B; non-GAAP EPS guidance $35.50–$36.50.
  • Regulatory updates: EBGLYSS approved; Jaypirca recommended in EU; forglipron filings ongoing.
  • Pipeline/BD: retatrutide Phase 3 obesity data; Indiana manufacturing expansion & acquisitions.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.